Literature DB >> 19822295

Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.

Katia Gagne1, Marc Busson, Jean-Denis Bignon, Marie-Lorraine Balère-Appert, Pascale Loiseau, Anne Dormoy, Valérie Dubois, Pascale Perrier, Isabelle Jollet, Monique Bois, Dominique Masson, Agnès Moine, Léna Absi, Didier Blaise, Dominique Charron, Colette Raffoux.   

Abstract

Given their antileukemic activity, natural killer (NK) cells can alter the outcome of hematopoietic stem cell transplantation (HSCT). The physiologic functions of NK cells are regulated by the interaction of killer immunoglobulin-like receptors (KIR) with specific HLA class I ligands. In the literature, different models based on HLA class I and/or KIR donor (D)/recipient (R) gene disparities are considered as predictors of NK cell alloreactivity. In this retrospective and multicentric French study, we analyzed the clinical impact of the different NK-alloreactivity models in 264 patients who underwent T repleted unrelated HSCT. First, we did not observe that the "KIR ligand-ligand" model had a significant clinical impact on unrelated HSCT outcome, whereas the "missing KIR ligand" model had a significant but limited effect on unrelated HSCT, because only the absence of C1 ligand in patients with myelogenous diseases was associated with a decreased overall survival (OS) (hazard ratio=2.17, P=.005). The "KIR receptor-receptor" and the "KIR receptor-ligand" models seemed the most capable of predicting NK alloreactivity because they had a significant impact on acute graft-versus-host disease (aGVHD) occurrence, OS, and relapse incidence in D/R unrelated pairs. In particular, KIR3DL1 gene mismatches in the GVH direction (D(+)R(-)) and the D KIR3DL1(+)/3DS1(+) and R Bw4(-) combination were respectively correlated with the lowest OS in HLA identical pairs (HR=1.99, P =.02) and the highest incidence of relapse in HLA nonidentical D/R unrelated pairs (HR=4.72, P =.03). Overall, our results suggest a detrimental effect of KIR3DL1(+)/3DS1(+) donor NK cells transplanted into HLA-Bw4(-) patients in the absence of an educational process via KIR3DL1/HLA-Bw4 interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822295     DOI: 10.1016/j.bbmt.2009.06.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  22 in total

1.  Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Authors:  D-F Chen; V K Prasad; G Broadwater; N L Reinsmoen; A DeOliveira; A Clark; K M Sullivan; J P Chute; M E Horwitz; C Gasparetto; G D Long; Y Yang; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-12-05       Impact factor: 5.483

2.  HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

Authors:  Ann Woolfrey; John P Klein; Michael Haagenson; Stephen Spellman; Effie Petersdorf; Machteld Oudshoorn; James Gajewski; Gregory A Hale; John Horan; Minoo Battiwalla; Susana R Marino; Michelle Setterholm; Olle Ringden; Carolyn Hurley; Neal Flomenberg; Claudio Anasetti; Marcelo Fernandez-Vina; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

3.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

4.  Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.

Authors:  Ronald M Sobecks; Tao Wang; Medhat Askar; Meighan M Gallagher; Michael Haagenson; Stephen Spellman; Marcelo Fernandez-Vina; Karl-Johan Malmberg; Carlheinz Müller; Minoo Battiwalla; James Gajewski; Michael R Verneris; Olle Ringdén; Susana Marino; Stella Davies; Jason Dehn; Martin Bornhäuser; Yoshihiro Inamoto; Ann Woolfrey; Peter Shaw; Marilyn Pollack; Daniel Weisdorf; Jeffrey Milller; Carolyn Hurley; Stephanie J Lee; Katharine Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-08       Impact factor: 5.742

5.  Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples.

Authors:  Aimee Merino; Rakhi Malhotra; Matt Morton; Joseph Mulenga; Susan Allen; Eric Hunter; Jianming Tang; Richard A Kaslow
Journal:  J Infect Dis       Date:  2011-01-07       Impact factor: 5.226

6.  HLA-F on Autologous HIV-Infected Cells Activates Primary NK Cells Expressing the Activating Killer Immunoglobulin-Like Receptor KIR3DS1.

Authors:  Zahra Kiani; Julie Bruneau; Daniel E Geraghty; Nicole F Bernard
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

7.  KIR Donor Selection: Feasibility in Identifying better Donors.

Authors:  Daniel Weisdorf; Sarah Cooley; Tao Wang; Elizabeth Trachtenberg; Michael D Haagenson; Cynthia Vierra-Green; Stephen Spellman; Ashley Spahn; Jenny Vogel; Hati Kobusingye; Todd Fehninger; Ann Woolfrey; Steven Devine; Maureen Ross; Edmund K Waller; Ronald Sobecks; Peter Parham; Lisbeth A Guethlein; Steven G E Marsh; Jeffrey Miller
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-24       Impact factor: 5.742

8.  A method for killer-cell immunoglobulin-like receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma.

Authors:  Aniqa Shahid; Denis R Chopera; Eric Martin; Kali A Penney; M-J Milloy; Zabrina L Brumme
Journal:  J Immunol Methods       Date:  2013-03-21       Impact factor: 2.303

9.  Role of KIR3DS1 in human diseases.

Authors:  Christian Körner; Marcus Altfeld
Journal:  Front Immunol       Date:  2012-11-01       Impact factor: 7.561

10.  The role of KIR genes and ligands in leukemia surveillance.

Authors:  Florian Babor; Johannes C Fischer; Markus Uhrberg
Journal:  Front Immunol       Date:  2013-02-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.